Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$113.95 USD

113.95
820,385

+0.18 (0.16%)

Updated Oct 4, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis Migraine Drug Accepted, AMD Positive in Phase III

by Zacks Equity Research

Novartis (NVS) announced that the EMA accepted its application for migraine candidate AMG 334.

    Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada

    by Zacks Equity Research

    Health Canada granted a Notice of Compliance (NOC) for Vemlidy 25mg tablets, a once-daily treatment for adults with chronic HBV infection with compensated liver disease.

      Amgen's Xgeva Myeloma Label Expansion sBLA Accepted by FDA

      by Zacks Equity Research

      Amgen Inc. (AMGN) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) to expand the label of its key drug, Xgeva.

        Novartis (NVS) Biosimilar of MabThera Approved in the EU

        by Zacks Equity Research

        Novartis AG (NVS) announced that its generic arm, Sandoz, has received European Commission (EC) approval for Rixathon.

          Arpita Dutt headshot

          3 Biotech Stocks That More than Doubled Year to Date

          by Arpita Dutt

          Here is a look at Puma (PBYI) and two other biotech stocks that have recorded massive gains so far in 2017.

            Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx

            by Zacks Equity Research

            Novartis AG (NVS) announced positive data on arthritis drug Cosentyx from two phase III studies.

              Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval

              by Zacks Equity Research

              Puma's stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry in the year so far after an FDA advisory committee recommended approval for neratinib in May this year.

                Why Is ImmunoGen (IMGN) Stock Up 131% This Year?

                by Zacks Equity Research

                Shares of ImmunoGen, Inc. (IMGN) are massively up 130.9% this year so far, outperforming the the Zacks classified Medical-Drugs industry's registered 3.6% increase during this period.

                  Why is Alnylam's (ALNY) Stock Close to 100% this Year?

                  by Zacks Equity Research

                  Shares of Alnylam Pharmaceuticals, Inc. (ALNY) soared 93.3% this year so far massively outperforming the 2.6% increase registered by the Zacks classified Biomed/Genetics industry during this period.

                    Coherus Stock Plummets as FDA Rejects Neulasta Biosimilar

                    by Zacks Equity Research

                    Coherus Biosciences, Inc. (CHRS) shares declined nearly 24% in yesterday's trading as it announced that it has received a complete response letter (CRL) from the FDA for its biosimilar version of Amgen Inc's (AMGN) blockbuster drug, Neulasta.

                      Novartis Presents Positive Data on CAR-T Cell Therapy Drug

                      by Zacks Equity Research

                      Novartis AG (NVS) announced data from an interim analysis from a phase II study on lymphoma candidate.

                        Why is Kite Pharma (KITE) Stock Up Close to 100% this Year?

                        by Zacks Equity Research

                        Shares of Kite Pharma, Inc. (KITE) were up around 5.6% on Thursday.

                          Teva Migraine Candidate Succeeds in Second Phase III Study

                          by Zacks Equity Research

                          Teva announced that its experimental migraine prevention candidate, fremanezumab, met all the primary and secondary endpoints in a second late-stage study.

                            Jazz Pharma Sleep Disorder Candidate Positive in Phase III

                            by Zacks Equity Research

                            Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy results from studies evaluating its lead pipeline candidate, JZP-110, in adult patients with excessive sleepiness (ES) associated with narcolepsy and obstructive sleep apnea (OSA).

                              Novartis' (NVS) Tasigna Receives Label Update Nod in EU

                              by Zacks Equity Research

                              Novartis AG (NVS) announced that the EC has approved the inclusion of Treatment-free Remission (TFR) data in the oncology drug Tasigna's label.

                                Novartis, Bristol-Myers Collaborate for Opdivo Combination

                                by Zacks Equity Research

                                Novartis AG (NVS) and Bristol-Myers Squibb Company (BMY) collaborate for Opdivo combination therapies.

                                  Roche Announces Data on Perjeta, Alecensa and Tecentriq

                                  by Zacks Equity Research

                                  Roche announced a series of data on various cancer drugs like Perjeta, Alecensa and Tecentriq at ASCO.

                                    Novartis Presents Data on Tafinlar-Mekinist Combination

                                    by Zacks Equity Research

                                    Novartis AG (NVS) announced results from a phase II study, BRF113220, on the combination of Tafinlar and Mekinist at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO).

                                      Amgen (AMGN) Presents Positive Clinical Data on Cancer Drugs

                                      by Zacks Equity Research

                                      Amgen, Inc. (AMGN) presented encouraging results from a phase III study, evaluating its marketed drug Xgeva (denosumab) for an expanded indication at the American Society of Clinical Oncology.

                                        Radius (RDUS) Announces Positive Data on Breast Cancer Drug

                                        by Zacks Equity Research

                                        Radius Health, Inc. (RDUS) announced encouraging results from an ongoing phase I study on pipeline candidate elacestrant (RAD1901) in patients suffering from estrogen receptor positive (ER+) breast cancer.

                                          Pfizer Provides Final Update on Phase II Talazoparib Study

                                          by Zacks Equity Research

                                          Pfizer Inc. (PFE) announced data from its phase II study, ABRAZO, which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1/2 positive (gBRCA+) mutations, showing anti-tumor activity

                                            Novartis Reports Positive Data on Breast Cancer Drug Kisqali

                                            by Zacks Equity Research

                                            Novartis AG (NVS) announced positive data from the phase III study, MONALEESA-2 on breast cancer drug Kisqali.

                                              Aduro's Drug Gets Clearance by the FDA for Solid Tumors

                                              by Zacks Equity Research

                                              Aduro Biotech, Inc. (ADRO) announced that the FDA has cleared the Investigational New Drug application (IND) for its pipeline candidate ADU-S100 (MIW815).

                                                Novartis Biosimilar Pipeline, 2018 Growth Plans on Track

                                                by Zacks Equity Research

                                                Novartis AG (NVS) announced that the EMA has accepted its applications for biosimilar versions of AbbVie's (ABBV) Humira (adalimumab) and Johnson & Johnson's (JNJ) Remicade (infliximab) for review.

                                                  Arpita Dutt headshot

                                                  5 Drug Stocks in Focus on World MS Day

                                                  by Arpita Dutt

                                                  Life with MS -- this world MS day, here's a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market.